DUBLIN–(BUSINESS WIRE)–The “U.S. Real-World Evidence Solutions Market by Component, Application, End User – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029
Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market.
Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE.
Market Dynamics
Drivers
Growing Burden of Chronic and Infectious Diseases
Rising Focus Towards Personalized Healthcare
Delays in Drug Development and the Subsequent Increase in Development Costs
Shift Towards Value-Based Care
Rapidly Growing Big Data in Healthcare
Restraints
Reluctance to Rely on Real-World Studies
Opportunities
Rising Focus on End-to-End RWE Services
Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
Challenges
Lack of Standardized Methodologies to Develop RWE
Key Market Trends
Growing Adoption of RWE in Drug Development and Commercialization
Rising Number of Consolidations
Improved Patient Outcomes and Value Creation from Real-World Evidence
Scope of the Report
U.S. RWE Solutions Market, by Component
Datasets
Disparate Datasets
EMR/EHR/Clinical Data
Claims & Billing Data
Pharmacy Data
Product/Disease Registries Data
Other Disparate Datasets
Integrated Datasets
Consulting and Analytics
U.S. RWE Solutions Market, by Application
Market Access & Reimbursement/Coverage Decisions
Drug Development & Approvals
Oncology
Neurology
Immunology
Cardiovascular Diseases
Other Therapeutic Areas
Post Market Surveillance
Medical Device Development & Approvals
Clinical and Regulatory Decision-Making
U.S. RWE Solutions Market, by End User
Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Regulatory Analysis – U.S. Real-World Evidence (RWE) Solutions Market
6. Pricing Models (EMR/Genomic/Integrated Datasets)
7. U.S. Real-World Evidence Solutions Market, by Component
8. U.S. Real-World Evidence Solutions Market, by Application
9. U.S. Real-World Evidence Solutions Market, by End User
10. Competitive Landscape
11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)
Companies Mentioned
Anthem Inc. (U.S.)
Clinigen Group plc (U.K.)
Cognizant Technology Solutions Corporation (U.S.)
IBM Corporation (U.S.)
ICON plc (Ireland)
IQVIA HOLDINGS INC. (U.S.)
Oracle Corporation (U.S.)
PAREXEL International Corporation (U.S.)
PerkinElmer Inc. (U.S.)
PPD Inc. (U.S.)
SAS Institute Inc. (U.S.)
UnitedHealth Group Incorporated (U.S.)
Flatiron Health Inc. (U.S.)
For more information about this report visit https://www.researchandmarkets.com/r/wzw62r
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
